MedTrace Logo

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

NCT06031376 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2023-09-11

No results posted yet for this study

Summary

Fruquintinib with PD-1 inhibitors (FP) and TAS-102 with bevacizumab (TB) are two common therapies for patients with previous-treated metastatic colorectal cancer (mCRC). However, it's still not clear that which therapy can bring better prognosis. Our study sought to investigate the efficacy and safety of fruquintinib with PD-1 Inhibitors versus TAS-102 with bevacizumab in Late-Line mCRC between July 2019 to October 2022July 2019 and June 2021 at the Hunan Cancer Hospital.

Conditions

  • Metastatic Colorectal Adenocarcinoma

Interventions

DRUG

Fruquintinib

5mg once daily for 14 days on/7 days off, over a 21-day cycle

DRUG

PD-1 inhibitors

The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.

DRUG

Trifluridine/Tipiracil

TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days

DRUG

Bevacizumab

Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Principal Investigators

  • Rongrong li, professor · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2022-10-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031376 on ClinicalTrials.gov